Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ter, Genzyme

generated approximately $373 million in cash from net income prior to

one-time events and proceeds from the issuance of common stock. The

company invested approximately $122 million in capital projects to

expand manufacturing capacity to meet current and anticipated product

demand. The company also made a $150 million investment in Isis

Pharmaceuticals associated with the license of mipomersen, a highly

promising product candidate in late-stage development.

-- Genzyme is also using a portion of its operating cash flow to

repurchase shares under a three-year program to reduce the dilutive

effect of equity compensation. The company repurchased 1 million

shares in the first quarter and has repurchased approximately 4.5

million shares since this program began one year ago.

"We had a very strong first quarter to start the year," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "We continue to focus on our commitment to deliver 20 percent non-GAAP earnings growth through 2011, while building the company to ensure that we sustain our growth over the longer term."

Financial Guidance

-- Genzyme expects 2008 non-GAAP earnings of approximately $3.90 per

diluted share, compared with prior guidance of $4.00 per diluted share.

This previously announced adjustment reflects the delay in FDA approval

of 2000L production capacity for Myozyme.

-- GAAP earnings in 2008 are expected to be approximately $2.65 per

diluted share, compared with prior guidance of approximately $2.75 per

diluted share. GAAP figures include anticipated amortization and

stock-compensation expenses and the effect of contingent convertible

debt.

-- Genzyme reaffirmed its commitment to 20 percent growth in compound non-

GAAP earnings per share through 2011. No
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) announced ... has granted fast track designation for carfilzomib, a next ... with relapsed and refractory multiple myeloma. The Fast Track ... the development, and expedite the review of drugs to ...
... SAN FRANCISCO, Jan. 31, 2011 DNA Direct, a ... MHS ) and a leading provider of ... that Aspirus Wausau Hospital of Wausau, Wisconsin, Atlantic Health ... Rochester, Michigan and Swedish Covenant Hospital of Chicago, Illinois, ...
... Frontier Global Sciences, a leading scientific laboratory ... today it has expanded its capabilities to include ... instrument. The purchase of a Perkin Elmer Nexion ... ICP-MS services including standard quadropole, true dynamic reaction ...
Cached Biology Technology:Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 2Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 3Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 4Four Community Hospitals Join DNA Direct's Genomic Medicine Network 2Four Community Hospitals Join DNA Direct's Genomic Medicine Network 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced today ... to confirm its adherence to current U.S. Food and ... conduct regulated smart device and smart phone application trials ... quality. "HITLAB is determined to improve global ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Soybean production has continued to increase in the Northeast ... the crop and many experienced growers planting alongside corn crops. ... with a corn planter in 30-inch rows instead of 7.5-inch ... a Cornell University scientist, investigated the response of two soybean ...
... L. Boren announced today that OU is establishing an ... expertise to benefit Oklahoma and the nation, including emerging ... led by a national expert, who will be appointed ... million gift from Corix, a multi-utility infrastructure company, which ...
... grant totaling $2.2 million shows how the University of ... using technology to advance the cutting-edge field of personalized ... their genetic make-up. The grant also highlights the ... Institute (CCTSI) to bring scientific discoveries to the bedside ...
Cached Biology News:OU establishes a new water and sustainability institute 2OU establishes a new water and sustainability institute 3Personalizing medicine 2Personalizing medicine 3